Ferlapioside: a new bromine substituted iridoid glycoside from the roots of Korovin.

One new bromine substituted iridoid glycoside, ferlapioside (), was isolated from the roots of Korovin, together with 10 known ones including seven iridoid glycosides (-) and three sesquiterpene lactones (-). Their structures were elucidated by extensive spectroscopic analyses, e.g.

[Stroke in children: experience of the Center for the Treatment of Cerebrovascular Diseases in Children and Adolescents in Moscow].

Objective: To analyze the work of the Center for the Treatment of Cerebrovascular Pathology in Children and Adolescents, operating on the basis of the Morozov Children's City Clinical Hospital of the Moscow Health Department for the period 2018-2021 and to assess the peculiarities of organizing the provision of specialized care to children and adolescents with acute cerebrovascular accident (ACA).

Material And Methods: Annual reports of the Center for the period 2018-2021; included children and adolescents aged 1 month to 17 years 11 months 29 days, with new onset ischemic stroke (IS) and hemorrhagic stroke (HS), cerebral venous thrombosis (sinus thrombosis), confirmed clinically and radiologically.

Results: Statistical data on stroke and organization of care for children with this pathology in Moscow are presented.

Association of gene polymorphisms with body weight changes in prediabetic patients.

Background: Recent research has demonstrated that Type 2 Diabetes (T2D) risk is influenced by a number of common polymorphisms, including MC4R rs17782313, PPARG rs1801282, and TCF7L2 rs7903146. Knowledge of the association between these single nucleotide polymorphisms (SNPs) and body weight changes in different forms of prediabetes treatment is still limited. The aim of this study was to investigate the association of polymorphisms within the MC4R, PPARG, and TCF7L2 genes on the risk of carbohydrate metabolism disorders and body composition changes in overweight or obese patients with early carbohydrate metabolism disorders.

[The Berlipril and Retalzem treatment of hypertension patients: the dynamics of the clinico-hemodynamic indices and of the vasodilating humoral factors].

Submitted in the paper are data on clinical, hemodynamic, and neurohumoral effects of monotherapy with an inhibitor of the angiotensin-converting enzyme berlipril (enalapril maleate) and a calcium antagonist of the benzothiazepine series retalzem (diltiazem resinate) versus their combination therapy. The combination therapy offers a number of important advantages over monotherapy with the above-named agents, consisting in apparent hypotensive action and a greater activation of endothelium-derived vasodilating and antiaggregation substances.